Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $1,247.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE